Continued Research and Development Expenditure
First written in FY2016-Q2. 18 of 32 entries say "Restated". Latest entry: FY2026-H1.
26 other companies' latest entry also says "Other".
- FY2026-H1Decline in R&D expenditure for the interim periodAnnual report
「Total R&D expenses for the current interim consolidated accounting period were ¥120.739 million (¥127.235 million in the same period of the previous year). There were no material changes in the status of the Group's R&D activities during the current interim consolidated accounting period.」
Although there were no material changes in R&D activities, interim R&D expenses decreased from ¥127.235 million in the same period of the previous year to ¥120.739 million. - FY2025Annual R&D expenses decreasedAnnual report
「Total R&D expenses for the current consolidated fiscal year were ¥254.296 million.」
While the R&D process has continued, annual R&D expenses decreased from ¥259.169 million in the previous fiscal year to ¥254.296 million. - FY2025-H1AdvancedAnnual report
「Total R&D expenses for the current interim consolidated accounting period were ¥127.235 million (¥120.269 million in the same period of the previous year).」
R&D expenses for the interim period were ¥127.235 million, up from ¥120.269 million in the same period of the previous year. - FY2024AdvancedAnnual report
「The R&D division conducts its activities with the aim of creating safe, reliable products that contribute to society, taking into account technological trends that are undergoing dramatic change toward the realization of a decarbonized society. In product development, we chemically synthesize candidate substances, evaluate the functions they exhibit in physical property tests, and, based on the results, continuously propose high-value-added products to leading companies in each field, leading to sales. Total R&D expenses for the current consolidated fiscal year were ¥259.169 million.」
R&D expenses increased from ¥240.396 million in the previous fiscal year to ¥259.169 million. The process of chemical synthesis, physical property testing, customer proposals and commercialization is also described in specific terms. - FY2024-Q2AdvancedAnnual report
「Total R&D expenses for the cumulative second quarter of the current consolidated fiscal year were ¥120.269 million (¥112.952 million in the same period of the previous year). There were no material changes in the status of the Group's R&D activities during the cumulative second quarter of the current consolidated fiscal year.」
Although there were no material changes in R&D activities, R&D expenses increased from ¥112.952 million in the same period of the previous year to ¥120.269 million. - FY2024-Q1AdvancedAnnual report
「Total R&D expenses for the three-month cumulative consolidated period were ¥61.159 million (¥57.801 million in the same period of the previous year). There were no material changes in the status of the Company's group's R&D activities during the three-month cumulative consolidated period.」
Although there were no material changes in R&D activities, R&D expenses increased from ¥57.801 million in the same quarter of the previous year to ¥61.159 million. - FY2023Slight decline in annual R&D expensesAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥240.396 million.」
Annual R&D expenses were ¥240.396 million, down from ¥244.961 million in the previous year. - FY2023-Q3Slight increase in R&D expensesAnnual report
「Total R&D expenses for the nine-month cumulative consolidated period were ¥176.353 million (¥176.213 million in the same period of the previous year). There were no material changes in the status of the Company's group's R&D activities during the nine-month cumulative consolidated period.」
While there were no material changes in R&D activities, R&D expenses edged up from ¥176.213 million in the same period of the previous year to ¥176.353 million. - FY2023-Q2Slight decrease in R&D expensesAnnual report
「Total R&D expenses for the six-month cumulative consolidated period were ¥112.952 million (¥115.824 million in the same period of the previous year). There were no material changes in the status of the Company's group's R&D activities during the six-month cumulative consolidated period.」
While there were no material changes in R&D activities, R&D expenses decreased from ¥115.824 million in the same period of the previous year to ¥112.952 million. - FY2022Slight decline in annual R&D expensesAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥244.961 million.」
Annual R&D expenses were ¥244.961 million, down from ¥249.077 million in the previous year. - FY2022-Q3Slight year-on-year decline in R&D expensesAnnual report
「Total R&D expenses for the nine-month cumulative consolidated period were ¥176.213 million (¥179.140 million in the same period of the previous year). There were no material changes in the status of the Company's group's R&D activities during the nine-month cumulative consolidated period.」
While there were no material changes in R&D activities, R&D expenses decreased from ¥179.140 million in the same period of the previous year to ¥176.213 million. - FY2022-Q2RestatedAnnual report
「Total R&D expenses for the six-month cumulative consolidated period were ¥115.824 million (¥116.545 million in the same period of the previous year). There were no material changes in the status of the Company's group's R&D activities during the six-month cumulative consolidated period.」
The company states that there were no material changes in R&D activities and discloses R&D expenses of ¥115.824 million for the six-month cumulative period. - FY2022-Q1RestatedAnnual report
「Total R&D expenses for the three-month cumulative consolidated period were ¥56.637 million (¥56.552 million in the same period of the previous year). There were no material changes in the status of the Company's group's R&D activities during the three-month cumulative consolidated period.」
The company states that there were no material changes in R&D activities and discloses R&D expenses of ¥56.637 million for the first quarter. - FY2021AdvancedAnnual report
「Total R&D expenses for the year were ¥249.077 million.」
Annual R&D expenses were ¥249.077 million, up from ¥235.837 million in the previous year. The company also describes the development of high-performance, high-quality specialty chemicals and new dehydration-condensation agents for medical applications. - FY2021-Q3AdvancedAnnual report
「Total R&D expenses for the nine-month cumulative consolidated period were ¥179.140 million (¥168.095 million in the same period of the previous year). There were no material changes in the status of the Company's group's R&D activities during the nine-month cumulative consolidated period.」
While stating that there were no material changes in R&D activities, the company reports that R&D expenses increased from ¥168.095 million in the same period of the previous year to ¥179.140 million. - FY2021-Q2RestatedAnnual report
「Total R&D expenses for the six-month cumulative consolidated period were ¥116.545 million (¥112.036 million in the same period of the previous year). There were no material changes in the status of the Company's group's R&D activities during the six-month cumulative consolidated period.」
While stating that there were no material changes in R&D activities, the company discloses R&D expenses of ¥116.545 million. - FY2021-Q1RestatedAnnual report
「Total R&D expenses for the three-month cumulative consolidated period were ¥56.552 million (¥54.199 million in the same period of the previous year). There were no material changes in the status of the Company's group's R&D activities during the three-month cumulative consolidated period.」
The company states that there were no material changes in R&D activities and discloses R&D expenses of ¥56.552 million. - FY2020-Q3RestatedAnnual report
「Total R&D expenses for the nine-month cumulative consolidated period were ¥168.095 million (¥166.240 million in the same period of the previous year). There were no material changes in the status of the Company's group's R&D activities during the nine-month cumulative consolidated period.」
The company states that there were no material changes in R&D activities and discloses R&D expenses of ¥168.095 million for the nine-month cumulative period. - FY2020-Q2RestatedAnnual report
「Total R&D expenses for the six-month cumulative consolidated period were ¥112.036 million (¥110.985 million in the same period of the previous year). There were no material changes in the status of the Company's group's R&D activities during the six-month cumulative consolidated period.」
The company states that there were no material changes in R&D activities and discloses R&D expenses of ¥112.036 million. - FY2020-Q1RestatedAnnual report
「Total R&D expenses for the three-month cumulative consolidated period were ¥54.199 million (¥51.587 million in the same period of the previous year). There were no material changes in the status of the Company's group's R&D activities during the three-month cumulative consolidated period.」
The company states that there were no material changes in R&D activities and discloses R&D expenses of ¥54.199 million. - FY2019RestatedAnnual report
「Total R&D expenses for the year were ¥225.243 million.」
R&D activities continued, and R&D expenses of ¥225.243 million for the year are disclosed. - FY2019-Q3RestatedAnnual report
「Total R&D expenses for the nine-month cumulative consolidated period were ¥166.240 million (¥176.185 million in the same period of the previous year). There were no material changes in the status of the Company's group's R&D activities during the nine-month cumulative consolidated period.」
The company states that there were no material changes in R&D activities and discloses R&D expenses of ¥166.240 million for the nine-month cumulative period. - FY2019-Q2RestatedAnnual report
「Total R&D expenses for the six-month cumulative consolidated period were ¥110.985 million (¥120.316 million in the same period of the previous year). There were no material changes in the status of the Company's group's R&D activities during the six-month cumulative consolidated period.」
The company states that there were no material changes in R&D activities and discloses R&D expenses of ¥110.985 million. - FY2019-Q1RestatedAnnual report
「Total R&D expenses for the three-month cumulative consolidated period were ¥51.587 million (¥55.584 million in the same period of the previous year). There were no material changes in the status of the Company's group's R&D activities during the three-month cumulative consolidated period.」
The company states that there were no material changes in R&D activities and discloses R&D expenses of ¥51.587 million for the quarter. - FY2018-Q3RestatedAnnual report
「Total R&D expenses for the nine-month cumulative consolidated period were ¥176.185 million (¥136.654 million in the same period of the previous year). There were no material changes in the status of the Company's group's R&D activities during the nine-month cumulative consolidated period.」
While stating that there were no material changes in R&D activities, the company discloses R&D expenses of ¥176.185 million. - FY2018-Q1RestatedAnnual report
「Total R&D expenses for the three-month cumulative consolidated period were ¥55.584 million (¥45.808 million in the same period of the previous year). There were no material changes in the status of the Company's group's R&D activities during the three-month cumulative consolidated period.」
While stating that there were no material changes in R&D activities, the company discloses R&D expenses of ¥55.584 million. - FY2017-Q3RestatedAnnual report
「Total R&D expenses for the nine-month cumulative consolidated period were ¥136.654 million (¥126.802 million in the same period of the previous year). There were no material changes in the status of the Company's group's R&D activities during the nine-month cumulative consolidated period.」
The company states that there were no material changes in R&D activities and discloses R&D expenses of ¥136.654 million. - FY2017-Q2RestatedAnnual report
「Total R&D expenses for the six-month cumulative consolidated period were ¥93.490 million (¥82.540 million in the same period of the previous year). There were no material changes in the status of the Company's group's R&D activities during the six-month cumulative consolidated period.」
While stating that there were no material changes in R&D activities, the company discloses R&D expenses of ¥93.490 million. - FY2017-Q1RestatedAnnual report
「Total R&D expenses for the three-month cumulative consolidated period were ¥45.808 million (¥41.956 million in the same period of the previous year). There were no material changes in the status of the Company's group's R&D activities during the three-month cumulative consolidated period.」
The absence of material changes in R&D activities was confirmed, and quarterly R&D expenses of ¥45.808 million are disclosed. - FY2016RestatedAnnual report
「As the maturation of related rubber industries, including automotive tires, has become pronounced with the development of an advanced consumer society in recent years, our basic R&D policy is to expand non-rubber chemicals. Based on surveys of market and technology trends in the target fields, we are developing high-value-added specialty chemicals. Total R&D expenses for the year were ¥167.481 million.」
The direction of R&D and annual R&D expenses of ¥167.481 million are disclosed. The policy of expanding non-rubber chemicals has been separated into a new thread. - FY2016-Q3RestatedAnnual report
「Total R&D expenses for the nine-month cumulative consolidated period were ¥126.802 million (¥128.184 million in the same period of the previous year). There were no material changes in the status of the Company's group's R&D activities during the nine-month cumulative consolidated period.」
No material changes were made to R&D activities, and cumulative R&D expenses of ¥126.802 million are disclosed. - FY2016-Q2First statedAnnual report
「Total research and development expenses for the six-month period ended December 31 were ¥82,540 thousand, compared with ¥80,397 thousand in the same period of the previous year.」
R&D expenditure for the cumulative quarterly period was disclosed in numerical terms.